Status:
COMPLETED
First-in-human Study to Assess Safety and Tolerability of a Single Subcutaneous Dose of SAR441255 in Lean to Overweight Subjects
Lead Sponsor:
Sanofi
Conditions:
Overweight
Healthy Subjects
Eligibility:
All Genders
18-55 years
Phase:
PHASE1
Brief Summary
Primary Objective: To assess the safety and tolerability of SAR441255 after ascending single subcutaneous (SC) doses Secondary Objectives: To assess the pharmacokinetic parameters of SAR441255 in p...
Detailed Description
Study duration per participant is approximately 8 weeks including a 21-day screening and baseline phase, a 4-day treatment phase and a 28-day follow up period after dosing.
Eligibility Criteria
Inclusion
- Inclusion criteria :
- Male and female subjects, between 18 and 55 years of age, inclusive
- Body Mass Index ≥20 and ≤30 kg/m2
- Body weight between 65 and 90 kg, inclusive
- No concomitant medication
- Fasting Plasma Glucose \<126 mg/dL
- Hemoglobin A1c \<6.5%
- Triglycerides \<300 mg/dL
- Low-density lipoprotein (LDL) Cholesterol \<200 mg/dL
- Permanent sterile or postmenopausal, if female
- Exclusion criteria:
- Any history or presence of clinically relevant cardiovascular, pulmonary, gastrointestinal, hepatic, renal, metabolic, hematological, neurological, osteomuscular, articular, psychiatric, systemic, gynecologic (if female), ocular, or infectious disease, or signs of acute illness.
- Any medication (including over the counter products and any other herbal/alternative remedies such as St John's Wort) within 14 days before inclusion or within 5 times the elimination half-life or pharmacodynamic half-life of the medication; any vaccination within the last 28 days and any biologics (antibody or its derivatives) given within 4 months before inclusion.
- The above information is not intended to contain all considerations relevant to a patient's potential participation in a clinical trial.
Exclusion
Key Trial Info
Start Date :
April 25 2019
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
September 26 2019
Estimated Enrollment :
48 Patients enrolled
Trial Details
Trial ID
NCT04521738
Start Date
April 25 2019
End Date
September 26 2019
Last Update
September 22 2025
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Investigational site number 8400001
Knoxville, Tennessee, United States, 37920